Abstract
Type 2 diabetes mellitus is a major risk factor for both cardiovascular and kidney disease, with a shorter life expectancy than in people without diabetes. Until the last decade, the main therapeutic focus was on management of hyperglycemia, although the correction of associated abnormalities such as dyslipidemia, hypertension, hypercoagulability, obesity, and insulin resistance, were important secondary therapeutic goals.1 Close glycemic control was shown to exert beneficial effects on diabetes-specific microvascular complications, including retinopathy, nephropathy, and neuropathy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
